Chiral gamma lactam derivatives or its pharmaceutically acceptable salts and preparing method thereof
A chiral gamma lactam derivative or its salts, produced using specific catalysts, addresses the limitations of current Parkinson's treatments by inhibiting neuronal death and muscle atrophy, providing effective symptom management and muscle enhancement for Parkinson's disease and related conditions.
Patent Information
- Application Number
- KR1020230114561
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-08-31
- Filing Date
- 2023-08-30
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-08-30
AI Technical Summary
Current treatments for Parkinson's disease primarily focus on replenishing dopamine levels, leading to side effects like dyskinesia and psychiatric disorders, and lack effective solutions for muscle atrophy associated with the disease, while the production of lactam compounds is hindered by the instability of carbonylnitrene intermediates.
Development of a chiral gamma lactam derivative or pharmaceutically acceptable salts thereof, utilizing specific organic chiral catalysts to produce gamma lactam derivatives in high purity, which inhibit neuronal cell death, normalize dopamine pathways, increase motor function, and enhance muscle mass, addressing muscle atrophy and neurodegenerative symptoms.
The chiral gamma lactam derivative or its salts exhibit MAO-B and MSTN inhibitory effects, offering superior symptom control for Parkinson's disease and improving muscle diseases, mental disorders, and neurodegenerative conditions, with potential as a novel therapeutic agent.
Smart Images

Figure 112023095770210-PAT00111_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a composition for the prevention, improvement, or treatment of muscular diseases, mental diseases, or degenerative neurological diseases comprising said derivative or said pharmaceutically acceptable salt thereof. Background Technology
[0003] Globally, more than 80% of people aged 65 or older suffer from one or more chronic diseases, and more than 68% suffer from two or more chronic diseases. A representative example of the aforementioned chronic disease is Parkinson's disease.
[0004] Parkinson's disease is a progressive neurodegenerative disorder characterized by symptoms such as slow movement, resting tremor, muscle rigidity, dragging gait, and stooped posture. It is morphologically characterized by the specific death of dopaminergic cells located in the substantia nigra. While the growth of reactive cytoplasms (ROS), oxidative stress, abnormal protein structure, and mitochondrial damage have been identified as causes, the exact cause has not yet been determined.
[0005] Therefore, when treating Parkinson's disease, the treatment drug must be selected considering the patient's age, the severity of symptoms, and the side effects of the drug. It is known that dopamine agonists such as Mirapex or Requip and MAO-B inhibitors are administered for the treatment of early-stage Parkinson's disease, while dopamine agonists, MAO-B inhibitors, and COMT inhibitors are administered in combination with levodopa for the treatment of late-stage Parkinson's disease with motor fluctuations.
[0006] Although global pharmaceutical companies are developing drugs to treat Parkinson's disease, most have dropped out during the clinical trial phase. As an alternative, there have been attempts to regulate these substances at the level of receptors or transcription factors, but the results are still insufficient. Currently used anti-Parkinson's drugs have several fundamental limitations. They primarily involve simply replenishing the dopamine deficiency—the main cause of Parkinson's symptoms—by quantity (dopa therapy), or using dopamine agonists with significant side effects; thus, most drugs serve to delay the worsening of symptoms rather than provide a cure.
[0007] Since the fundamental pathological phenomenon of Parkinson's disease is the death of neurons in the substantia nigra of the midbrain, the most fundamental and complete treatment method is to inhibit the death of dopamine neurons and normalize the dopamine production pathway (neuronormalization). On the other hand, existing medications continue to exhibit side effects such as dyskinesia and various forms of psychiatric disorders. Consequently, it is evident that they have limitations in that they cannot serve as a fundamental cure for the dopaminergic nervous system.
[0008] In other words, conventional treatments for Parkinson's disease have been developed primarily based on dopamine agonists and MAO-B inhibitors, but no research has been conducted on the development of muscle atrophy caused by motor disorders in Parkinson's disease, and there are virtually no treatments available domestically or internationally that have a mechanism to restore such muscle atrophy.
[0009] Globally, there are approximately 6.3 million patients with Parkinson's disease, and the market size amounts to about 4 trillion won. In Korea, the number of patients exceeds 100,000, and the market size is estimated at about 300 billion won. Particularly, the incidence rate is high among the elderly population aged 60 or older (about 1–2%), and as it is one of the diseases with a significant impact as society ages, it is a challenge that must be overcome to realize a healthy society.
[0011] Meanwhile, lactams are used as primary raw materials for pharmaceuticals and materials chemistry that possess high bioactivity, serving as very important intermediates in medicine, materials science, materials chemistry, and synthetic chemistry. For example, beta-lactams include penicillin, the first lactam discovered by humans, and Zetia, which shows excellent efficacy against cardiovascular diseases; levetiracetam, composed of a gamma-lactam backbone, is used for epilepsy; and azaspiren, known for its ability to inhibit angiogenesis, is being applied as a treatment for uterine cancer. As such, lactams possess biological activity and are widely used as actual drugs, serving as key raw materials for new drug development.
[0012] Lactams are the core components of complex organic molecules and serve as the basic framework widely utilized in pharmaceuticals, synthetic chemistry, and materials; however, research and development regarding the catalytic reactions required for the production of lactam compounds had been stalled for some time. This was because carbonylnitrene, a key intermediate in the reaction to convert hydrocarbons into lactam compounds, decomposed too easily into byproducts at room temperature. In other words, the Curtius rearrangement process was the biggest obstacle to lactam production. Therefore, there is an urgent need to develop new catalysts to solve this problem.
[0014] Against this backdrop, the inventors have made diligent efforts to solve the problems of the prior art as described above. As a result, they have confirmed that when using an organic chiral catalyst compound having a specific structure, gamma lactam derivatives or pharmaceutically acceptable salts thereof can be produced in large quantities with high purity using a small amount of catalyst, and have completed the present invention by confirming that they can be utilized as a therapeutic agent capable of simultaneously inhibiting neuronal cell death, neuroprotection, normalizing dopamine pathways, increasing motor function, anticonvulsant effects, and increasing muscle mass. The problem to be solved
[0016] The object of the present invention is to provide a chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof.
[0017] Another object of the present invention is to provide a composition for the prevention, improvement, or treatment of muscular diseases, mental diseases, or degenerative neurological diseases comprising the above derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
[0018] Another object of the present invention is to provide a method for preparing the derivative or a pharmaceutically acceptable salt thereof.
[0019] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below. means of solving the problem
[0021] To solve the above problem, the present invention may provide a pharmaceutical composition for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases comprising, as an active ingredient, one or more selected from the group consisting of: a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1a] below; a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1b] below; a chiral gamma lactam derivative represented by [Chemical Formula 1c] below or a pharmaceutically acceptable salt thereof; and combinations thereof. In this case, the derivative or the pharmaceutically acceptable salt thereof includes a racemic mixture, a solvate, etc.
[0022] [Chemical Formula 1a]
[0023] ;
[0024] [Chemical Formula 1b]
[0025] ;
[0026] [Chemical Formula 1c]
[0027] .
[0028] As one embodiment of the present invention, a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1c] below may be one or more selected from the group consisting of hydrochloride, bromate, sulfate, phosphate, nitrate, citrate, acetate, lactate, tartrate, maleate, gluconate, succinate, formate, trifluoroacetate, oxalate, fumarate, glutarate, adipose, methanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, sodium salt, potassium salt, lithium salt, calcium salt, magnesium salt, and combinations thereof, but is not limited thereto. Preferably, it may be a hydrochloride, and more preferably, it may be a salt represented by [Chemical Formula 1d] below.
[0029] [Chemical Formula 1d]
[0030] .
[0031] In another embodiment of the present invention, the muscle disease may be one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, rigid spine syndrome, amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease, sarcopenia, and combinations thereof, but is not limited thereto.
[0032] In another embodiment of the present invention, the mental disorder may be one or more selected from the group consisting of depression, mania, bipolar disorder, schizophrenia, delirium, panic disorder, Attention-Deficit Hyperactivity Disorder (ADHD), cognitive disorder, anxiety disorder, post-traumatic stress disorder (PTSD), and combinations thereof, but is not limited thereto.
[0033] As another embodiment of the present invention, the degenerative neurological disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, spinocerebellar degeneration, spinocerebellar ataxia, Friedreich's ataxia, Macado-Joseph disease, dystonia, progressive supranuclear palsy, senile dementia, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, alcohol-related dementia, pre-senile dementia, temporal lobe It may be one or more selected from the group consisting of temporal lobe epilepsy, multiple sclerosis, cerebral amyloid angiopathy, systemic amyloidosis, Tourette's disorder, stroke, and combinations thereof, but is not limited thereto.
[0034] In addition, the present invention may provide one or more uses selected from the group consisting of: a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1a] for the manufacture of a drug for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases; a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1b]; a chiral gamma lactam derivative represented by [Chemical Formula 1c] or a pharmaceutically acceptable salt thereof; and combinations thereof.
[0035] In addition, the present invention may provide a method for preventing or treating a muscular disease, mental disease, or degenerative neurological disease, comprising the step of administering to an individual one or more selected from the group consisting of: a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1a]; a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1b]; a chiral gamma lactam derivative represented by [Chemical Formula 1c] or a pharmaceutically acceptable salt thereof; and combinations thereof.
[0036] In addition, the present invention may provide a cosmetic composition for the prevention or improvement of muscular diseases, mental diseases, or degenerative neurological diseases comprising, as an active ingredient, one or more selected from the group consisting of: a cosmetically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1a]; a cosmetically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1b]; a chiral gamma lactam derivative represented by [Chemical Formula 1c] or a cosmetically acceptable salt thereof; and combinations thereof.
[0037] In addition, the present invention may provide a food composition for the prevention or improvement of muscular diseases, mental diseases, or degenerative neurological diseases comprising, as an active ingredient, one or more selected from the group consisting of: a food-acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1a]; a food-acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1b]; a chiral gamma lactam derivative represented by [Chemical Formula 1c] or a food-acceptable salt thereof; and combinations thereof.
[0039] In addition, the present invention provides a method for preparing a pharmaceutical composition for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases, comprising as an active ingredient a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1a], comprising the following steps.
[0040] (1) A step of preparing a compound represented by [Chemical Formula 4a] from a compound represented by [Chemical Formula 3a] using a catalyst compound represented by [Chemical Formula 2];
[0041] (2) A step of preparing a compound represented by [Chemical Formula 5a] from a compound represented by [Chemical Formula 4a];
[0042] (3) A step of preparing a compound represented by [Chemical Formula 6a] from a compound represented by [Chemical Formula 5a]; and
[0043] (4) A step of preparing a compound represented by [Chemical Formula 1a] by treating a compound represented by [Chemical Formula 6a] with sodium hydride (NaH), ethyl bromoacetate (BrCH2COOEt), and ammonia (NH3);
[0044] [Chemical Formula 1a]
[0045] ;
[0046] [Chemical Formula 2]
[0047] ;
[0048] [Chemical Formula 3a]
[0049] ;
[0050] [Chemical Formula 4a]
[0051] ;
[0052] [Chemical Formula 5a]
[0053] ;
[0054] [Chemical Formula 6a]
[0055] ;
[0056] In the above formula 2, R1 and R2 are identical or different from each other and are each one or more selected from the group consisting of hydrogen, a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, a C3-C8 aryl group, and combinations thereof; R3 is a C3-C8 aryl group, and one or more hydrogens of the aryl group are unsubstituted or substituted with one or more selected from the group consisting of a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, and combinations thereof; and in the above formula 5a, R4 may be hydrogen or a halogen group.
[0057] As one embodiment of the present invention, the catalyst compound represented by [Chemical Formula 2] may be one or more selected from the group consisting of catalyst compounds listed in Table 1 below and combinations thereof, but is not limited thereto.
[0058] 화학식 번호 화합물 번호 화합물명 화학식 2-1 1a 1-((1R,2R)-2-(3,5-bis(trifluoromethyl)benzylamino)-1,2-diphenylethyl)-3-(3,5-bis(trifluoromethyl)phenyl)thiourea 2-2 1b 1-[(1R,2R)-2-(Pentan-3-ylamino)-1,2-diphenylethyl]-3-(p-tolyl)thiourea 2-3 1c 1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea 2-4 1d 1-[(1R,2R)-2-(Pentan-3-ylamino)-1,2-diphenylethyl]-3-[4-(trifluoromethyl) phenyl]thiourea 2-5 1e 1-[(1R,2R)-2-(Pentan-3-ylamino)-1,2-diphenylethyl]-3-(perfluorophenyl)thiourea 2-6 1f 1-(4-Nitrophenyl)-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea 2-7 1g 1-(4-Cyanophenyl)-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea 2-8 1h 1-(4-Fluorophenyl)-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea 2-9 1i 1-((1R,2R)-2-(benzhydrylamino)-1,2-diphenylethyl)-3-(3,5-bis(trifluoromethyl)phenyl)thiourea 2-10 1j 1-((1R,2R)-2-(benzhydrylamino)-1,2-diphenylethyl)-3-(4-(trifluoromethyl)phenyl)thiourea 2-11 1k 1-((1R,2R)-2-(3,5-dimethylbenzylamino)-1,2-diphenylethyl)-3-(3,5-dimethylphenyl)thiourea
[0059] As another embodiment of the present invention, the compound represented by [Chemical Formula 5a] may be one or more selected from the group consisting of compounds listed in Table 2 below and combinations thereof, but is not limited thereto.
[0060] 화학식 번호 화합물 번호 화합물명 화학식 5a-1 4a (S)-Phenyl 4-nitro-3-phenylbutanoate 5a-2 4b (S)-Phenyl 3-(4-chlorophenyl)-4-nitrobutanoate
[0061] In addition, the present invention may provide a method for preparing a pharmaceutical composition for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases, comprising as an active ingredient a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1b], comprising the following steps.
[0062] (1) A step of preparing a compound represented by [Chemical Formula 4b] from a compound represented by [Chemical Formula 3b] using a catalyst compound represented by [Chemical Formula 2];
[0063] (2) A step of preparing a compound represented by [Chemical Formula 5b] from a compound represented by [Chemical Formula 4b];
[0064] (3) A step of preparing a compound represented by [Chemical Formula 6b] from a compound represented by [Chemical Formula 5b]; and
[0065] (4) A step of preparing a compound represented by [Chemical Formula 1b] by treating a compound represented by [Chemical Formula 6b] with sodium hydride (NaH), ethyl bromoacetate (BrCH2COOEt), and ammonia (NH3);
[0066] [Chemical Formula 1b]
[0067] ;
[0068] [Chemical Formula 2]
[0069] ;
[0070] [Chemical Formula 3b]
[0071] ;
[0072] [Chemical Formula 4b]
[0073] ;
[0074] [Chemical Formula 5b]
[0075] ;
[0076] [Chemical Formula 6b]
[0077] ;
[0078] In the above formula 2, R1 and R2 are identical or different from each other and are each one or more selected from the group consisting of hydrogen, a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, a C3-C8 aryl group, and combinations thereof; R3 is a C3-C8 aryl group, and one or more hydrogens of the aryl group are unsubstituted or substituted with one or more selected from the group consisting of a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, and combinations thereof; and in the above formula 5b, R4 is hydrogen or a halogen group, and R5 may be a C1-C6 alkyl group or a benzyl group.
[0079] As one embodiment of the present invention, the catalyst compound represented by [Chemical Formula 2] may be one or more selected from the group consisting of the catalyst compounds listed in Table 1 and combinations thereof, but is not limited thereto.
[0080] As another embodiment of the present invention, the compound represented by [Chemical Formula 5b] may be one or more selected from the group consisting of compounds listed in Table 3 below and combinations thereof, but is not limited thereto.
[0081] Chemical formula number Compound number compound name chemical formula 5b-1 2a (R)-Dimethyl 2-(2-nitro-1-phenylethyl)malonate 5b-2 2b (R)-Diethyl 2-(2-nitro-1-phenylethyl)malonate 5b-3 2c (R)-Diisopropyl 2-(2-nitro-1-phenylethyl)malonate 5b-4 2d (R)-Dipropyl 2-(2-nitro-1-phenylethyl)malonate 5b-5 2e (R)-Benzyl-2-carbobenzyloxy-4-nitro-3-phenylbutyrate 5b-6 2f (R)-dibutyl 2-(2-nitro-1-phenylethyl)malonate 5b-7 2g (R)-Diethyl 2-[1-(4-bromophenyl)-2-nitroethyl]malonate 5b-8 2h (R)-diethyl 2-(1-(4-chlorophenyl)-2-nitroethyl)malonate
[0082] In addition, the present invention may provide a method for preparing a pharmaceutical composition for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases, comprising as an active ingredient a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Chemical Formula 1d], comprising the following steps.
[0083] (1) A step of preparing a compound represented by [Chemical Formula 4b] from a compound represented by [Chemical Formula 3b] using a catalyst compound represented by [Chemical Formula 2];
[0084] (2) A step of preparing a compound represented by [Chemical Formula 5b] from a compound represented by [Chemical Formula 4b];
[0085] (3) A step of preparing a compound represented by [Chemical Formula 6b] from a compound represented by [Chemical Formula 5b]; and
[0086] (4) A step of preparing a compound represented by [Chemical Formula 1d] by treating a compound represented by [Chemical Formula 6b] with sodium hydride (NaH), ethyl bromoacetate (BrCH2COOEt), and hydrazine hydrate;
[0087] [Chemical Formula 1d]
[0088] ;
[0089] [Chemical Formula 2]
[0090] ;
[0091] [Chemical Formula 3b]
[0092] ;
[0093] [Chemical Formula 4b]
[0094] ;
[0095] [Chemical Formula 5b]
[0096] ;
[0097] [Chemical Formula 6b]
[0098] ;
[0099] In the above formula 2, R1 and R2 are identical or different from each other and are each one or more selected from the group consisting of hydrogen, a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, a C3-C8 aryl group, and combinations thereof; R3 is a C3-C8 aryl group, and one or more hydrogens of the aryl group are unsubstituted or substituted with one or more selected from the group consisting of a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, and combinations thereof; and in the above formula 5b, R4 is hydrogen or a halogen group, and R5 may be a C1-C6 alkyl group or a benzyl group.
[0100] As one embodiment of the present invention, the catalyst compound represented by [Chemical Formula 2] may be one or more selected from the group consisting of the catalyst compounds listed in Table 1 and combinations thereof, but is not limited thereto.
[0101] As another embodiment of the present invention, the compound represented by [Chemical Formula 5b] may be one or more selected from the group consisting of compounds listed in Table 3 and combinations thereof, but is not limited thereto.
[0103] In the present invention, the term “substitution” refers to a reaction that replaces an atom or atomic group contained in a molecule of a compound with another atom or atomic group.
[0104] In the present invention, the term “alkyl group” refers to a group derived from a straight-chain, branched-chain, or cyclic saturated aliphatic hydrocarbon having a specified number of carbon atoms and at least one valence. Examples of such alkyl groups may include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, 2-butyl, 3-butyl, pentyl, n-hexyl, cyclobutyl, cyclopentyl, and cyclohexyl groups.
[0105] In the present invention, the term "aryl group" refers to an unsaturated aromatic ring compound having 6 to 20 carbon atoms having a single ring (e.g., phenyl) or a plurality of condensed rings (e.g., naphthyl). Examples of such aryls may include, but are not limited to, phenyl groups, naphthyl groups, etc.
[0106] In the present invention, the term “alkoxy group” refers to an atomic group CnH2n+1O- formed by the bonding of an oxygen atom to an alkyl group, and examples of such alkoxy groups may include, but are not limited to, methoxy, ethoxy, propoxy, or ptoxy.
[0107] In the present invention, the term “halogen group” refers to elements belonging to Group 17 of the periodic table, such as fluorine (F), chloride (Cl), bromine (Br), or iodine (I), but is not limited thereto. Effects of the invention
[0109] A chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention has MAO-B and MSTN inhibitory efficacy and targets D1-mClu5, and can be utilized for the prevention, improvement, or treatment of muscle diseases including sarcopenia, mental diseases including depression, and neurodegenerative diseases including Parkinson's disease. In particular, the pharmaceutically acceptable salt can exhibit much superior efficacy in controlling Parkinson's disease symptoms compared to the derivative.
[0110] A method for preparing the derivative or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention is a chiral small molecule compound-based approach that is differentiated from conventional targets focused on dopamine agonists, and can preemptively lead a paradigm of novel therapeutic agents for muscle diseases, psychiatric diseases, or neurodegenerative diseases.
[0111] A method for preparing the derivative or a pharmaceutically acceptable salt thereof according to one embodiment of the present invention enables the preparation of a chiral gamma lactam derivative having high stereoselectivity or a pharmaceutically acceptable salt thereof using an appropriate amount of an organic catalyst base. Furthermore, the chiral gamma lactam derivative can be discovered as a core biomaterial and as a source core material for global biopharmaceuticals.
[0112] The effects of the chiral gamma lactam derivative or the pharmaceutically acceptable salt thereof and the method of preparing thereof according to one embodiment of the present invention are not limited to those mentioned above, and other effects not mentioned will be clearly understood by a person skilled in the art from the description below. Brief explanation of the drawing
[0114] Figure 1 is the result of confirming the calcium release of pH-30 (Formula 1b), a pharmaceutically acceptable salt of a chiral gamma lactam derivative according to one embodiment of the present invention, using a confocal laser scanning microscope (CLSM). Figure 2 shows the results of confirming the calcium release rates of the control group, rasagiline, and the comparative example, (R)-phenylpiracetam (Ph-piracetam). Figure 3 shows the results of confirming the calcium release rates of Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b), which are pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention. Figure 4 shows the effect of pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b), on the GDF-8 / Myostatin expression level (*p<0.05. **p<0.01. ***p<0.001). Figure 5 shows the effect of (a) SMAD2 and (b) SMAD3 expression levels of pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b) (*p<0.05. **p<0.01). Figure 6 shows the results of treating human neuroblastoma SH-SY5Y cell lines with pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b). Figure 6a confirms the expression levels of SYP, GAP-43, MAO-B, and iNOS, and Figure 6b confirms calcium release and the production of superoxide anions. FIG. 7 shows the results of performing an open field test (OFT) by treating a pharmaceutically acceptable salt of a chiral gamma lactam derivative according to one embodiment of the present invention. FIG. 7a shows the distance traveled when treated with Ph-30 (Formula 1b) at different concentrations, and FIG. 7b shows the distance traveled when treated with Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b) (*p<0.05. **p<0.01. ***p<0.001). FIG. 8 shows the results of a forced swim test (FST) performed by treating with pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b) (*p<0.05. **p<0.01. ***p<0.001). FIG. 9 shows the results of performing a rotarod test by treating with Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b), which are pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention. FIG. 9a shows how much the drop time from an accelerating rotarod (ARR) was delayed, FIG. 9b shows the muscle weight of the tibialis anterior (TA), and FIG. 9c shows the muscle weight of the extensor digitorum longus (EDL) (*p<0.05. **p<0.01. ***p<0.001). Figure 10 shows the number of convulsive seizures when treated with pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b) (**p<0.01). Figure 11 shows the effect of pharmaceutically acceptable salts of chiral gamma lactam derivatives according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b), on the level of GDF-8 / Myostatin expression in mouse serum (*p<0.05. **p<0.01). Specific details for implementing the invention
[0115] The inventors have solved the difficulties in synthesizing the chiral catalyst and the problem of excessive use of the chiral catalyst in the synthesis of gamma lactam derivatives using conventional chiral catalysts, and have solved the problem of mass production by shortening the reaction time.
[0116] Specifically, the inventors prepared a non-natural gamma-lactam derivative with high stereoselectivity from a nitro compound or a pharmaceutically acceptable salt thereof using a difunctional organic caral catalyst compound with excellent stereoselectivity. In addition, the inhibitory efficacy of the synthesized chiral gamma-lactam derivative or the pharmaceutically acceptable salt thereof on MAO-B and MSTN, as well as behavioral experiments and studies on changes in brain activity, were confirmed to have preventive, corrective, or therapeutic effects on muscular diseases, mental diseases, or neurodegenerative diseases.
[0117] From the above results, the present invention provides a pharmaceutical composition for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases comprising a chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof as an active ingredient as listed in Table 4 below.
[0118] Chemical formula number Compound number compound name chemical formula 1a 5a(Ph-20) (S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide hydrochloride 1b 5b(Ph-30) (R)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide hydrochloride 1c (R)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetohydrazide 1d 5c(Ph-10) (R)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetohydrazide hydrochloride
[0119] In addition, the present invention may provide for the use of chiral gamma lactam derivatives or pharmaceutically acceptable salts thereof for the manufacture of drugs for the prevention or treatment of muscular diseases, mental diseases, or degenerative neurological diseases.
[0120] In addition, the present invention may provide a method for preventing or treating muscular diseases, mental diseases, or degenerative neurological diseases, comprising the step of administering the chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof to an individual.
[0121] In the present invention, the term “pharmaceuticalally acceptable salt” refers to a formulation of a compound that does not cause severe irritation to an organism to which the compound is administered and does not impair the biological activity and physical properties of the compound. The pharmaceutically acceptable salt may be obtained by reacting the compound of the present invention with an inorganic acid such as hydrochloric acid, bromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfonic acid such as methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, or an organic carboxylic acid such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, capric acid, isobutanoic acid, malonic acid, succinic acid, phthalic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc. In addition, the compound of the present invention may be obtained by reacting it with a base to form salts such as ammonium salts, alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as calcium or magnesium salts, salts of organic bases such as dicyclohexylamine, N-methyl-D-glucarmine, and tris(hydroxymethyl)methylamine, and amino acid salts such as arginine and lysine. Furthermore, it may include not only pharmaceutically acceptable salts but also all salts, hydrates, and solvates that can be prepared by conventional methods.
[0122] In the present invention, the term "prevention" refers to any act of suppressing or delaying the occurrence, spread, or recurrence of geriatric diseases such as muscle disease, depression, and Parkinson's disease through the administration of the composition of the present invention, and the term "treatment" refers to any act of improving or beneficially altering the symptoms of said disease through the administration of the composition of the present invention.
[0123] In the present invention, the term "pharmaceutical composition" means that it is prepared for the purpose of preventing or treating the above disease, and can be formulated into various forms according to conventional methods. For example, it can be formulated into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and can be formulated into external preparations, suppositories, and sterile injectable solutions.
[0124] In the present invention, "included as an active ingredient" means that the corresponding ingredient is included in an amount necessary or sufficient to realize the desired biological effect. In actual application, the amount included as an active ingredient is determined as an amount for treating the target disease, taking into account factors that do not cause other toxicities, and may vary depending on various factors such as, for example, the disease or condition being treated, the form of the composition administered, the size of the subject, or the severity of the disease or condition. A person skilled in the art to which the present invention pertains can empirically determine the effective amount of an individual composition without involving excessive experimentation.
[0125] In addition, the pharmaceutical composition of the present invention may include one or more pharmaceutically acceptable carriers in addition to the active ingredients described above, depending on each formulation.
[0126] The above-mentioned pharmaceutically acceptable carrier may be saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components, and may further include other conventional additives such as antioxidants, buffers, and bacteriostatic agents as needed. Additionally, by additionally adding diluents, dispersants, surfactants, binders, and lubricants, it may be formulated into injectable formulations such as aqueous solutions, suspensions, and emulsions, or into pills, capsules, granules, or tablets. Furthermore, it may be preferably formulated according to each disease or component by appropriate methods in the art or by using methods disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton, PA).
[0127] The composition of the present invention may be administered orally or parenterally in a pharmaceutically effective amount according to the intended method, and the term “pharmaceutically effective amount” of the present invention means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level may be determined based on factors including the patient’s health status, severity, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field.
[0128] In the present invention, the term “individual” is not limited to mammals such as livestock or humans that require prevention, treatment, and / or diagnosis of the disease, but preferably may be a human.
[0129] The pharmaceutical composition of the present invention can be formulated into various forms for administration to individuals, and representative formulations for parenteral administration are injectable formulations, preferably isotonic aqueous solutions or suspensions. Injectable formulations can be prepared according to techniques known in the art using suitable dispersants or wetting agents and suspending agents. For example, each component can be dissolved in saline solution or buffer solution to form an injectable formulation. Additionally, formulations for oral administration include, for example, ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers, and these formulations may include, in addition to the active ingredient, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and a lubricant (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol). The above tablet may include a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and optionally may further include a disintegrant such as starch, agar, alginic acid or its sodium salt, an absorbent, a coloring agent, a flavoring agent and / or a sweetener. The above formulation may be prepared by conventional mixing, granulation, or coating methods.
[0130] In addition, the pharmaceutical composition of the present invention may further include adjuvants such as preservatives, hydrating agents, emulsification promoters, salts or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated according to conventional methods.
[0131] The pharmaceutical composition according to the present invention may be administered via various routes including oral, transdermal, subcutaneous, intravenous, or intramuscular, and the dosage of the active ingredient may be appropriately selected according to various factors such as the route of administration, the patient's age, gender, body weight, and severity of the patient. In addition, the composition of the present invention may be administered in combination with known compounds that can enhance the desired effect.
[0132] The pharmaceutical composition according to the present invention may be administered to humans and animals by route of administration, either orally or parenterally, such as intravenously, subcutaneously, intranasally, or intraperitoneally. Oral administration includes sublingual application. Parenteral administration includes injection methods such as subcutaneous injection, intramuscular injection, and intravenous injection, as well as drip methods.
[0133] In addition, the pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration, and method of administration as long as it exhibits the effects of the present invention, and the pharmaceutical composition of the present invention may additionally include known agents as active ingredients in addition to the chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof, and may be used in combination with other treatments known for the treatment of these diseases.
[0135] The terms used in the embodiments are for illustrative purposes only and should not be interpreted as intended to be limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.
[0136] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.
[0137] In describing the components of the embodiments, terms such as first, second, A, B, (a), (b), etc., may be used. These terms are intended merely to distinguish the components from other components, and the nature, order, or sequence of the components is not limited by these terms. Where it is stated that a component is "connected," "combined," or "joined" to another component, it should be understood that the component may be directly connected or joined to the other component, but that another component may also be "connected," "combined," or "joined" between each component.
[0139] Hereinafter, embodiments are described in detail with reference to the attached drawings. However, various modifications may be made to the embodiments, and thus the scope of the patent application is not limited or restricted by these embodiments. It should be understood that all modifications, equivalents, and substitutions to the embodiments are included within the scope of the rights.
[0140] In addition, when describing with reference to the attached drawings, identical components are assigned the same reference numeral regardless of drawing symbols, and redundant descriptions thereof are omitted. In describing the embodiments, if it is determined that a detailed description of related prior art could unnecessarily obscure the essence of the embodiments, such detailed description is omitted.
[0142] The present invention is capable of various modifications and may have various embodiments. Specific embodiments are illustrated in the drawings and described in detail in the detailed description below. However, this is not intended to limit the present invention to specific embodiments, and it should be understood that it includes all modifications, equivalents, and substitutions that fall within the spirit and scope of the present invention. In describing the present invention, detailed descriptions of related prior art are omitted if it is determined that such detailed descriptions may obscure the essence of the present invention.
[0144] Example 1. Preparation of the organic chiral catalyst compound of the present invention
[0145] A method for preparing an organic chiral catalyst compound, namely an arylated thiourea catalyst, according to one embodiment of the present invention is shown in Reaction Scheme 1 below.
[0146] [Reaction Equation 1]
[0147]
[0148] Thiourea (0.95 equivalents) was added to a suspension of (R,R)-1,2-diphenylethylenediamine (1.0 equivalents) in toluene (0.5 M) at 0 °C, and the mixture was stirred for 30 seconds. The product was vacuum concentrated and purified by flash column chromatography on a silica gel containing ethyl (methanol / methylene chloride 1:20). An alkyl ketone (1.1 equivalents) was added to thiourea-substituted DPEN (1.0 equivalents) in CH2Cl2 (0.1 M), and the mixture was stirred at room temperature for 1 hour. NaBH4 (2.0 equivalents) and ethanol were added at 0 °C, and the mixture was stirred at room temperature for 1 hour. The product was filtered through a Celite filter, and the mixture was extracted with ethyl acetate. The combined organic extract was washed with brine, dried (MgSO4), and vacuum concentrated. The product was purified by chromatography on a silica gel column (methanol / methylene chloride 1:20) to obtain a pure amide product (quantitative yield) as a brown foamed solid.
[0149] Specific examples of the above organic chiral catalyst compounds are as shown in Table 5 below.
[0150] Chemical formula number Compound number R1 R2 R3 2-1 1a H 3,5-(CF3)2-Ph 3,5-(CF3)2-Ph 2-2 1b ethyl ethyl 4-CH3-Ph 2-3 1c ethyl ethyl 3,5-(CF3)2-Ph 2-4 1d ethyl ethyl 4-CF3-Ph 2-5 1e ethyl ethyl C6F5 2-6 1f ethyl ethyl 4-NO2-Ph 2-7 1g ethyl ethyl 4-CN-Ph 2-8 1h ethyl ethyl 4-F-Ph 2-9 1i phenyl phenyl 3,5-(CF3)2-Ph 2-10 1j phenyl phenyl 4-CF3-Ph 2-11 1k H 3,5-(CH3)2-Ph 3,5-(CH3)2-Ph
[0151] (1)1-((1R,2R)-2-(3,5-bis(trifluoromethyl)benzylamino)-1,2-diphenylethyl)-3-(3,5-bis(trifluoromethyl)phenyl)thiourea( 1a , Chemical formula 2-1)
[0152] 93% yield; [α] D 20 =+0.45 (c=0.11, CH2Cl2); 1 H NMR (500 MHz, DMSO-d6) δ(br, 3 H), 7.39~7.29 (m, 16 H), 4.54 (s, 4 H); 13C NMR (100 MHz, DMSO-d6) δ171.58, 157.99, 142.12,131.46, 134.14, 129.17, 127.28, 125.67, 122.96, 112.29, 89.59, 89.05, 84.78; IR (KBr) 3032.6, 2871.3, 1663.5, 1386.6, 1275.9, 1117.5, 930.2, 700.2 cm -1 ; HRMS (FAB + ) for C 32 H 23 F 12 N3S [M+H] + Calcd: 709.1421, Found: 709.1428
[0153] (2)1-[(1R,2R)-2-(Pentan-3-ylamino)-1,2-diphenylethyl]-3-(p-tolyl)thiourea( 1b , 화학식 2-2)
[0154] 86% yield; [α] D 20 =+0.19 (c=1.00, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(s, 1 H), 7.89 (d, J=7.0 Hz, 1 H), 7.32~7.18 (m, 14 H), 5.44 (s, 1 H), 4.08 (d, J=5.1 Hz, 1 H), 2.29 (s, 2 H), 2.02 (s, 1 H), 1.39 (s, 1 H), 1.20~1.06 (m, 4 H), 0.68 (t, J=7.5 Hz, 3 H), 0.41 (t, J=7.1 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ141.83, 141.55, 136.71, 134.88, 130.03, 128.67, 128.51, 127.49, 127.40, 124.67, 64.28, 63.77, 55.84, 26.71, 24.02, 21.20, 10.94, 8.30; IR (KBr) 3180.2, 2958.4, 1948.8, 1510.1, 1240.1, 821.6, 700.1, 565.1 cm -1 ; HRMS (FAB + ) for C 27 H 34 N3S [M+H] + Calcd: 432.2473, Found: 432.6537, pattern 432.5, 345.3, 266.4, 176.3, 106.01
[0155] (3)1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea( 1c , 화학식 2-3)
[0156] 90% yield; [α] D 20 =+0.31 (c=0.11, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(br, 1 H), 8.30 (s, 2 H), 7.74 (s, 1 H), 7.40~7.19 (m, 10 H), 5.57 (br, 1 H), 4.18 (d, J=4.9 Hz, 1 H), 2.09 (m, 1 H), 1.24~1.20 (m, 4 H), 0.75 (t, J=7.1 Hz, 3 H), 0.50 (t, J=6.0 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ142.49, 140.88, 130.96, 130.64, 128.70, 128.59, 128.56, 127.60, 125.22, 122.52, 122.19, 116.70, 64.34, 63.62, 56.48, 26.64, 23.90, 10.98, 8.54; IR (KBr) 3239.9, 2964.2, 1471.5, 1278.6, 1135.9, 885.2, 700.1 cm -1 ; HRMS (FAB + ) for C 28 H 30 F6N3S [M+H] + Calcd: 554.2065, Found: 554.2065
[0157] (4)1-[(1R,2R)-2-(Pentan-3-ylamino)-1,2-diphenylethyl]-3-[4-(trifluoromethyl) phenyl]thiourea( 1d , 화학식 2-4)
[0158] 88% yield; [α] D 20 =+45.5 (c=0.02, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(br s, 1H), 8.41 (br s, 1H), 7.79 (d, J=8.0 Hz, 2H), 7.64 (d, J=8.5 Hz, 2H), 7.35~7.15 (m, 10H), 5.53 (br s, 1H), 4.13 (d, J=5.5 Hz, 1H), 2.07 (m, 1H), 1.30~1.15 (m, 4H), 0.73 (t, J=7.1 Hz, 3H), 0.49 (t, J=6.9 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ80.91, 143.97, 141.18, 128.64, 128.52, 127.69, 127.48, 126.29, 122.41, 64.43, 63.71, 56.32, 26.68, 23.98, 10.98, 8.53; IR(KBr) 3205.3, 2962.3, 1945.9, 1741.5, 1517.8, 1324.9, 1245.9, 1066.5, 840.9, 700.1, 597.9 cm -1 ; HRMS(FAB + ) for C 27 H 31 F3N3S[M+H] + Calcd: 486.2191, Found: 486.2190
[0159] (5)1-[(1R,2R)-2-(Pentan-3-ylamino)-1,2-diphenylethyl]-3-(perfluorophenyl)thiourea( 1e , 화학식 2-5)
[0160] 89% yield; [α] D 20 =+80.4 (c=0.02, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(s, 1 H), 8.61 (s, 1 H), 7.30~7.15 (m, 10 H), 5.48 (br s, 1 H), 4.13 (d, J=6.1 Hz, 1 H), 2.08 (m, 1 H), 1.54 (br, 1 H), 1.30~1.14 (m, 4 H), 0.74 (t, J=7.4 Hz, 3 H), 0.55 (t, J=6.3 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ145.82, 143.43, 141.90, 140.77, 139.01, 138.84, 136.56, 129.39, 128.61, 128.43, 127.68, 127.60, 115.93, 64.77, 64.53, 56.37, 26.72, 24.16, 10.86, 8.58; IR (KBr) 3299.8, 2964.2, 1525.5, 1344.2, 1145.6, 991.3, 912.2, 700.1, 605.6 cm -1 ; HRMS (FAB + ) for C 26 H 27 F5N3S [M+H] + Calcd: 508.1846, Found: 508.1848
[0161] (6)1-(4-Nitrophenyl)-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea( 1f , 화학식 2-6)
[0162] 89% yield; [α] D 20 =+37.7 (c=0.02, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(s, 1 H), 8.16 (m, 2 H), 7.90 (d, J=9.1 Hz, 2 H), 7.37~7.15 (m, 10 H), 5.54 (br s, 1 H), 4.16 (d, J=5.5 Hz, 1 H), 2.07 (m, 1 H), 1.30~1.15 (m, 4 H), 0.75 (t, J=7.4 Hz, 3 H), 0.50 (t, J=7.4 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ146.95, 142.46, 141.92, 140.92, 128.68, 128.56, 127.72, 125.16, 120.92, 64.35, 63.80, 56.35, 55.59, 26.70, 23.96, 11.03, 8.61; IR (KBr) 3330.5, 2960.2, 2599.6, 2456.4, 2345.0, 1951.6, 1743.3, 1496.5, 1346.1, 1110.8, 1072.2, 852.4, 700.0, 586.3 cm -1 ; HRMS (FAB + ) for C 26 H 31 N4O2S [M+H] + Calcd: 463.2168, Found: 463.2165
[0163] (7)1-(4-Cyanophenyl)-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea( 1g , 화학식 2-7)
[0164] 69% yield; [α] D 20 =+55.5 (c=0.02, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(br s, 1 H), 8.54 (br s, 1 H), 7.84~7.72 (m, 4 H), 7.35~7.17 (m, 10 H), 5.54 (br s, 1 H), 4.14 (d, J=5.2 Hz, 1 H), 2.07 (br s, 1 H), 1.56 (br s, 1 H), 1.21 (m, 4H), 0.74 (t, J=7.4 Hz, 3 H), 0.49 (t, J=6.9 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ144.83, 141.92, 141.05, 133.40, 128.67, 128.33, 127.68, 127.64, 127.51, 121.76, 119.76, 105.41, 64.41, 63.72, 60.43, 56.33, 26.74, 23.98, 21.42, 14.74, 11.02, 8.56; IR (KBr) 3317.0, 2960.2, 2360.4, 2225.5, 1949.7, 1739.5, 1508.1, 1315.2, 1176.4, 1072.2, 837.0, 700.0, 545.8 cm -1 ; HRMS (FAB + ) for C 27 H 31 N4S [M+H] + Calcd: 443.2269, Found: 443.2271
[0165] (8)1-(4-Fluorophenyl)-3-[(1R,2R)-2-(pentan-3-ylamino)-1,2-diphenylethyl]thiourea( 1h , 화학식 2-8)
[0166] 84% yield; [α] D 20 =+17.9 (c=0.02, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(s, 1 H), 8.00 (d, J=6.7 Hz, 1 H), 7.48~7.43 (m, 2 H), 7.31~7.16 (m, 11 H), 5.46 (br s, 1 H), 4.09 (d, J=5.22 Hz, 1 H), 2.03 (br s , 1 H), 1.44 (br s, 1 H), 1.14 (m, 4 H), 0.70 (t, J=10.1, 3 H), 0.44 (t, J=7.0 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ161.03, 158.62, 141.90, 141.44, 135.97, 128.65, 128.51, 127.57, 127.42, 126.49, 116.13, 115.90, 64.39, 63.76, 56.03, 26.72, 24.02, 10.98, 8.39; IR (KBr) 3193.7, 2962.3, 1889.9, 1511.9, 1218.8, 848.6, 701.9, 555.42 cm -1 ; HRMS (FAB + ) for C 26 H 31 FN3S[M+H] + Calcd: 436.6172, Found: 436.2223. patern 436.5, 349.3, 266.4, 176.3, 106.1
[0167] (9)1-((1R,2R)-2-(benzhydrylamino)-1,2-diphenylethyl)-3-(3,5-bis(trifluoromethyl)phenyl)thiourea( 1i , 화학식 2-9)
[0168] 95% yield; [α] D 20 =+0.39 (c=0.16, CH2Cl2); 1 H NMR (400 MHz, DMSO-d6) δ.82~7.09 (m, 23 H), 5.72 (s, 1 H), 3.98 (s, 1 H), 3.35 (s, 1 H), 2.47 (br, 1 H); 13 C NMR (100 MHz, DMSO-d6) δ156.63, 153.35,143.36, 142.03, 141.31, 138.68, 129.48, 129.34, 126.90, 125.59, 123.65, 122.55, 122.14, 70.83, 65.14, 55.50; IR (KBr) 3239.9, 2964.2, 1471.5, 1278.6, 1135.9, 885.2, 700.1 cm -1; HRMS (ESI + ) for C 28 H 30 F6N3S [M+H] + Calcd: 649.1986, Found: 649.1932
[0169] (10)1-((1R,2R)-2-(benzhydrylamino)-1,2-diphenylethyl)-3-(4-(trifluoromethyl)phenyl)thiourea( 1j , 화학식 2-10)
[0170] 89% yield; [α] D 20 =+124 (c 0.10, CH2Cl2); 1 H NMR (300 MHz, DMSO-d6) δ(br, 1H), 7.77~7.10 (m, 26H), 4.90 (s, 1H), 4.82 (s, 2H), 1.92 (s, 1H);IR(KBr) 3679.5, 3352.2, 2985.3, 1402.4, 1265.9, 1065.7, 726.8 cm -1 ; HRMS(FAB + ) for C 35 H 30 F3N3S [M+H] + Calcd: 581.2113, Found: 581.2133
[0171] (11)1-((1R,2R)-2-(3,5-dimethylbenzylamino)-1,2-diphenylethyl)-3-(3,5-dimethylphenyl)thiourea( 1k , 화학식 2-11)
[0172] 89% yield; [α] D 20 =+112 (c 0.13, CH2Cl2); 1H NMR (500 MHz, DMSO-d6) δ(t, 6H), 7.32 (d, 2H), 7.27 (d, 4H), 7.00 (s, 4H), 4.54 (s, 4H), 2.21 (s, 12H), 1.25 (br, 1H); 13 C NMR (100 MHz, DMSO-d6) δ157.71, 156.95, 143.07, 138.05, 131.22, 129.00, 128.93, 127.09, 127.03, 123.43, 118.64, 112.63, 70.28, 68.05, 67.38, 21.63;IR(KBr) 3155.0, 2960.2, 2360.4, 1951.6, 1735.6, 1469.5, 1294.0, 1241.9, 1006.7, 837.0, 700.0, 572.8 cm -1 ; HRMS(FAB + ) for C 26 H 30 F2N3S[M+H] + Calcd: 454.2129, Found: 454.2133.
[0174] Example 2. Preparation of (S)-Phenylpiracetam Hydrochloride (Chemical Formula 1a)
[0175] A method for preparing (S)-phenylpiracetam hydrochloride (Chemical Formula 1a), which is a pharmaceutically acceptable salt of a (S)-type chiral gamma lactam derivative according to one embodiment of the present invention, is shown in Reaction Scheme 2 below.
[0176] [Reaction Equation 2]
[0177]
[0178] Using organic chiral catalyst compound 1a prepared in Example 1, a Michael addition reaction was performed with nitroethyl ester in the presence of water as a solvent to determine the reaction time and yield of the α,β-unsaturated ketone compound. Specifically, α,β-unsaturated ketone (1.0 equivalent), nitroethyl ester (2.0 equivalent), and 0.1 to 0.001 mol% of organic chiral catalyst compound 1a were added to water (0.4 mL), and the reaction mixture was stirred at room temperature (rt). Subsequently, the reaction transition was monitored by TLC. After the reaction was complete, sodium hydroxide (1.0 equivalent) and ethanol were added, and the mixture was stirred at room temperature for 12 hours. Subsequently, the product was concentrated under reduced pressure to obtain the target product. The product was purified by chromatography on a silica-gel column (hexane / ethylene acetate, 10:1).
[0179] Example 2.1. (S)-4-Nitro-1,3-diphenyl-butan-1-one(3a, chemical formula 4a)
[0180]
[0181] [α] D 20 -18.5( c 1.0, CHCl3); 1 H NMR (500 MHz, CDCl3) δ7.91~7.92(m, 2H), 7.59~7.26(m, 8H), 4.85~4.81(dd, 1H), 4.71~4.67(dd, 1H), 4.26~4.20(m, 1H), 3.51~3.46(dd, 1H), 3.45~3.40(dd, 1H) ppm; 13 C NMR (125 MHz, CDCl3) δ 196.87, 139.15, 136.39, 133.60, 129.09, 128.77, 128.04, 127.90, 127.48, 79.58, 41.54, 39.30 ppm; IR(KBr) 3058, 3029, 2920, 1687, 1544, 1440, 1367, 1268, 1224, 1084, 988, 764, 703, 623, 559 cm -1 ; LRMS(ESI + ) for C16 H 15 NO3[M+Na] + Calcd: 292.1, Found: 292.1; HPLC [Chiralcel AD-H, hexane / 2-propanol = 90 / 10, flow rate = 1.0 mL / min, λ= 254 nm, retention times:(major) 12.8 min,(minor) 17.4 min]; R f ( SiO2, EtOAc / n- hexane = 1 / 5) = 0.40
[0183] Example 2.2. (S)-phenyl-4-nitrobutanoate derivative (Chemical Formula 5a)
[0184] (1) (S)-Phenyl 4-nitro-3-phenylbutanoate( 4a , 화학식 5a-1)
[0185]
[0186] [α] D 20 +7.7( c 1.0, CHCl3); 1 H NMR(500 MHz, CDCl3) δ 7.38~7.16(m, 8H), 6.87~6.85(m, 2H), 4.75~4.71(dd, J = 11.6, 6.6 Hz, 1H), 4.68~4.64(dd, J = 11.6, 6.4 Hz, 1H), 4.10~4.04(m, 1H), 3.04~3.0(dd, J = 13.7, 4.6 Hz, 1H), 2.99~2.94(dd, J = 13.7, 5.6 Hz, 1H) ppm; 13 C NMR(125 MHz, CDCl3) δ 169.33, 150.33, 137.96, 129.50, 129.22, 128.29, 127.55, 126.12, 121.39, 79.38, 40.38, 37.87 ppm; LRMS(ESI + ) for C16 H 15 NO4[M+Na] + Calcd: 308.1, Found: 308.1; R f ( SiO2, EtOAc / n- hexane = 1 / 5) = 0.40
[0187] (2) (S)-Phenyl 3-(4-chlorophenyl)-4-nitrobutanoate( 4b , 화학식 5a-2)
[0188]
[0189] [α] D 20 +20.8( c 1.0, CH2Cl2); 1 H NMR(500 MHz, CDCl3) δ 7.35~7.22(m, 7H), 6.92~6.90(m, 2H), 4.79~4.75(dd, J = 12.7, 7.3 Hz, 1H), 4.71~4.67(dd, J = 12.7, 7.9 Hz, 1H), 4.11~4.06(m, 1H), 3.08~3.03(dd, J = 14.7, 5.3 Hz, 1H), 3.01~2.96(dd, J = 14.7, 6.5 Hz, 1H) ppm; 13 C NMR(125 MHz, CDCl3) δ 169.01, 150.17, 136.37,134.23, 129.53, 129.43, 128.88, 126.20, 121.26, 79.08, 39.70, 37.67 ppm; LRMS(ESI + ) for C 16 H 14 ClNO4[M+Na] + Calcd: 342.1, Found: 342.1; R f ( SiO2, EtOAc / n- hexane = 1 / 5) = 0.31
[0191] Example 2.3. (S)-4-Phenylpyrrolidin-2-one(4c, chemical formula 6a)
[0192] [α] D 20 +33.3( c 1.0, MeOH);
[0193] 1 H NMR(500 MHz, CDCl3) δ 7.37~7.33(m, 2H), 7.29~7.27(m, 2H), 7.26~7.25(m, 1H), 5.92(br s, 1H), 3.81~3.77(m, 1H), 3.71(q, J = 8.0 Hz, 1H), 3.45~3.41(dd, J = 9.4, 2.0 Hz, 1H), 2.77~2.72(dd, J = 16.8, 8.7 Hz, 1H), 2.54~2.49(dd, J = 17.0, 8.5 Hz, 1H) ppm; 13 C NMR(125 MHz, CDCl3) δ 177.93, 142.14, 128.88, 127.13, 126.79, 49.60, 40.31, 38.02 ppm; LRMS(ESI + ) for C 10 H 11 NO[M+H] + Calcd: 162.1, Found: 162.2; HPLC [Chiralcel AD-H, hexane / 2-propanol = 90 / 10, flow rate =1.0 mL / min, λ = 254 nm, retention times:(minor) 15.2 min,(major) 19.4 min]; R f ( SiO2, EtOAc) = 0.30
[0195] Example 2.4. (S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide hydrochloride (5a, chemical formula 1a)
[0196] [α] D 20 = -7.3(c = 1.0, MeOH);
[0197] A solution of 4-phenyl-2-pyrrolidinone (1.0 equivalent) in 1,4-dioxane (30 ml) was added to a suspension of sodium hydride (1.1 equivalent) in 1,4-dioxane (30 ml). The mixture was heated at 90 °C for 30 minutes and then cooled to room temperature. Ethyl bromoacetate (1.1 eq.) was added, and the reaction mixture was refluxed at 120 °C for 6 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using an ethyl acetate-hexane mixture in a 1:1 ratio to obtain N-ethoxycarbonylmethyl-4-phenyl-2-pyrrolidinone. A solution of N-ethoxycarbonylmethyl-4-phenyl-2-pyrrolidinone (250 mg, 1.01 mM) in methanol (30 ml) was saturated with a gaseous ammonia stream for 5 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography with an ethyl acetate-hexane mixture 1:1 silica gel and concentrated under reduced pressure. The concentrate was added to 6N HCl and dissolved by stirring, then concentrated again under reduced pressure to obtain N-carbamoylmethyl-4-phenyl-2-pyrrolidinone chloride (85%).
[0198] 1 H NMR spectrum (DMSO- d 6), δ, ppm: 2.41 dd(1H, 3-H), 2.72 dd(1H, 3-H), 3.42 m(1H, 5-H), 3.59 m(1H, 4-H), 3.79 m(1H, 5-H), 4.00 dd(2H, NCHCO); 7.24-7.36 m(5H, Ph). 13 C NMR spectrum (DMSO- d 6), δC, ppm: 37.01, 38.48, 44.04, 54.55, 127.16, 127.35, 129.08, 143.35, 170.64, 173.84 pp; LRMS (ESI + ) for C 10 H 14 ClNO2[M] +Calcd: 254, Found: 254;
[0200] Example 3. Preparation of (R)-Phenylpiracetam Hydrochloride (Formula 1b)
[0201] A method for preparing (R)-phenylpiracetam hydrochloride (Formula 1b) and (R)-phenylpiracetam hydrazide hydrochloride (Formula 1d), which are pharmaceutically acceptable salts of (R)-type chiral gamma lactam derivatives according to one embodiment of the present invention, is shown in Reaction Scheme 3 below.
[0202] [Reaction Equation 3]
[0203]
[0204] a) Catalytic compound 1a (0.0001 mol %), water, room temperature, 48 hours; b) Magnesium monoperoxyphthalate hexahydrate (MMPP), Li2CO3, MeOH, 0 ℃, 1 hour; c) NiCl26H2O / NaBH4, MeOH, room temperature, 6 hours; d) (1) NaOH, EtOH, room temperature, 0.5 hours, (2) Toluene, reflux, 0.5 hours.
[0206] Example 3.1. (R)-Malonate derivative (Formula 5b)
[0207] A method for preparing an intermediate (R)-malonate derivative for the preparation of a pharmaceutically acceptable salt of the above (R)-type chiral gamma lactam derivative is shown in Reaction Scheme 4 below.
[0208] [Reaction Equation 4]
[0209]
[0211] α,β-unsaturated nitro compound with malonitrile (2.0 equivalents) and the organic chiral catalyst compound prepared in Example 1 1aIn the presence of (0.001 mol %), water (0.4 mL) was used as a solvent and mixed with trans-β-nitrostyrene (1.0 equivalent) and malononitrile (2.0 equivalent), and the reaction mixture was stirred at room temperature. The reaction transition was monitored by TLC, and after the reaction was complete, 6 N HCl was added and heated at 65 °C for 2 hours. After cooling the reaction mixture to room temperature, dialkyl carbonate (1.5 equivalents) was added, and the solution was heated at 100 °C for 3 hours while stirring. Subsequently, the homogeneous reaction mixture was cooled to room temperature, poured into a 10% aqueous NaHCO3 solution, and ethyl acetate (0.2 mL) was added to the reaction mixture. This solution was washed twice with water (2 × 1.0 mL), dried over magnesium sulfate, and concentrated to obtain the desired product. Afterwards, the product was purified by chromatography on a silica gel column (hexane / methylene chloride 2:1).
[0212] Under an argon atmosphere, NaBH4 (10 equivalents) was added at 0 °C to a suspension of the obtained Michael addition reaction product (1.0 equivalent, >99% ee) and NiCl2·6H2O (1.0 equivalent) in MeOH (8.0 mL). After stirring the reaction mixture at room temperature for 7.5 hours, the reaction mixture was quenched with NH4Cl and diluted with CHCl3. The organic layer was separated, filtered with MgSO4, and vacuum concentrated. The residue was chromatographed in silica gel (as solvent, MeOH / CHCl3 = 1:20) to obtain the desired product as a colorless powder.
[0213] (1) (R)-Dimethyl 2-(2-nitro-1-phenylethyl)malonate( 2a , Chemical formula 5b-1)
[0214]
[0215] [α] D 20 = -1.98( c1.33, CH2Cl2); 1 H NMR(300 MHz, CDCl3) δ7.40~7.15(m, 5H), 5.15~5.03(m, 1H), 4.93(dd, J = 4.5, 12.8 Hz, 1H), 4.88~4.76(m, 2H), 4.20(td, J = 4.5, 9.5 Hz, 1H), 3.76(d, J = 9.5 Hz, 1H), 1.24(d, J = 6.1 Hz, 3H), 1.07(d, J = 6.4 Hz, 3H), 1.01(d, J = 6.4 Hz, 3H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.1, 166.4, 136.3, 128.9, 128.3, 128.2, 77.9, 69.9, 69.5, 55.1, 42.9, 21.5, 21.4, 21.19, 21.17 ppm; IR(KBr) 3030, 2985,1727, 1557 cm -1 ; HRMS(ESI) for C 13 H 16 N1O6[M+H] + Calcd: 282.09721, Found: 282.09726; HPLC [Chiralcel AD-H, hexane / 2-propanol = 95 / 5, 1.0 mL / min, λ= 254 nm, retention times:(major) 23.3 min,(minor) 38.0 min].
[0216] (2) (R)-Diethyl 2-(2-nitro-1-phenylethyl)malonate( 2b , 화학식 5b-2)
[0217]
[0218] [α] D 20 = -4.61( c 0.23, CH2Cl2); 1H NMR(300 MHz, CDCl3) δ7.30~7.20(m, 5H), 4.93(dd, J = 4.6, 13.1 Hz, 1H), 4.86(dd, J = 9.2, 13.1 Hz, 1H), 4.24~4.17(m, 3H), 3.98~3.97(q, 2H), 3.81~3.79(d, 1H), 1.25(t, 3H), 1.03(t, 3H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.4, 166.8, 136.2, 128.8, 128.2, 77.4, 77.0, 76.7 62.1, 61.8, 54.9, 42.9, 13.9, 13.7 ppm; IR(KBr) 2989, 2938, 1731, 1557 cm -1 ; HRMS(ESI) for C 15 H 20 N1O6[M+H] + Calcd: 310.12851, Found: 310.12936; HPLC [Chiralcel AD-H, hexane / ethanol = 90 / 10, 1.0 mL / min, λ= 254 nm, retention times:(major) 11.5 min,(minor) 15.3 min].
[0219] (3) (R)-Diisopropyl 2-(2-nitro-1-phenylethyl)malonate( 2c , 화학식 5b-3)
[0220]
[0221] [α] D 20 = -1.24( c 1.00, CH2Cl2); 1 H NMR(300 MHz, CDCl3) δ 7.32~7.22(m, 5H), 5.10(dd, J = 5.0,13.1 Hz, 1H), 4.91~4.979(m, 3H), 4.21~4.19(m, 1H), 1.25(d, J= 2.0 Hz, 6H), 1.07(dd, J = 2.0,2.0 Hz, 6H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.27, 166.54, 136.47, 129.07, 128.34, 127.9, 78.15, 70.15, 69.75, 55.35, 43.14, 21.80, 21.67, 21.48 ppm; IR(KBr) 3029, 2956, 1737, 1558 cm -1 ; HRMS(ESI) for C 17 H 24 N1O6[M+H] + Calcd: 338.15981 Found: 338.16336; HPLC [Chiralcel AD-H, hexane / 2-propanol = 95 / 5, 1.0 mL / min, λ= 254 nm, retention times:(major) 14.8 min,(minor) 34.4 min].
[0222] (4) (R)-Dipropyl 2-(2-nitro-1-phenylethyl)malonate( 2d , 화학식 5b-4)
[0223]
[0224] [α] D 20 = -1.73( c 0.10, CH2Cl2); 1 H NMR(300 MHz, CDCl3) δ 7.31~7.22(m, 5H), 4.92~4.87(t, J = 5.0,9.5 Hz, 2H), 4.24(m, 1H), 4.15~4.09(m, 2H), 3.92~3.83(dd,s, J =6.6 9.7 Hz, 3H), 1.68~1.61(m, 2H), 1.49~1.42(m, 2H), 0.93~0.88(t, J = 7.4,7.4 Hz, 3H), 0.82~0.77(t, J= 7.4,7.4 Hz, 3H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.79, 167.17, 136.46, 129.14, 128.52, 128.17, 77.85, 67.86, 67.65, 55.17, 43.16, 21.97, 21.81, 10.48 ppm; IR(KBr) 3029, 2956, 1737, 1558 cm -1 ; HRMS(ESI) for C 17 H 24 N1O6[M+H] + Calcd: 338.15981 Found: 338.16336; HPLC [Chiralcel AD-H, hexane / 2-propanol = 95 / 5, 1.0 mL / min, λ= 254 nm, retention times:(major) 18.4 min,(minor) 38.9 min].
[0225] (5) (R)-Benzyl-2-carbobenzyloxy-4-nitro-3-phenylbutyrate( 2e , 화학식 5b-5)
[0226]
[0227] [α] D 20 = -3.25( c 0.10, CH2Cl2); 1H NMR(400 MHz, CDCl3) δ 7.33-7.25(m, 10H), 7.17-7.07(m, 5H), 5.16(d, 1H, J = 12.2 Hz), 5.18(d, 1H, JAB = 12.2 Hz), 4.93(S, 1H), 4.84-4.82(m, 2H), 4.28~4.22(q, 1H), 3.94(d, 1H, 9.3 Hz); 13C NMR(100 MHz, CDCl3) δ167.39, 166.78, 136.14, 134.85, 129.25, 128.90, 128.15, 77.63, 68.04, 67.86, 55.14, 43.16 ppm; IR(KBr) 3068, 3036, 2963, 1736, 1558, 1498, 1456, 1378, 1326, 1286, 1217, 1156, 1003, 975, 908, 562 cm -1 ; HRMS(EI) for C 25 H 23 N1O6[M+H] + Calcd: 433.1525 Found: 433.1525; HPLC [Chiralcel AD-H, hexane / 2-propanol = 70 / 30, 1.0 mL / min, λ= 254 nm, retention times:(major) 26.0 min,(minor) 24.1 min].
[0228] (6) (R)-dibutyl 2-(2-nitro-1-phenylethyl)malonate( 2f , 화학식 5b-6)
[0229]
[0230] [α] D 20 = -2.55( c 0.10, CH2Cl2); 1 H NMR(400 MHz, CDCl3) δ 7.31~7.22(m, 5H), 4.92~4.87(t, J= 5.0,9.5 Hz, 2H), 4.24(m, 1H), 4.15~4.09(m, 2H), 3.92~3.83(dd,s, J =6.6 9.7 Hz, 3H), 1.68~1.61(m, 2H), 1.49~1.42(m, 2H), 0.93~0.88(t, J = 7.4,7.4 Hz, 3H), 0.82~0.77(t, J = 7.4,7.4 Hz, 3H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.79, 167.17, 136.46, 129.14, 128.52, 128.17, 77.85, 67.86, 67.65, 55.17, 43.16, 21.97, 21.81, 10.48 ppm; HRMS(EI) for C 17 H 24 N1O6[M+H] + Calcd: 338.15981 Found: 338.16336; HPLC [Chiralcel AD-H, hexane / 2-propanol = 95 / 5, 1.0 mL / min, λ= 254 nm, retention times:(major) 18.4 min,(minor) 38.9 min].
[0231] (7) (R)-Diethyl 2-[1-(4-bromophenyl)-2-nitroethyl]malonate( 2g , 화학식 5b-7)
[0232]
[0233] [α] D 20 = -3.56( c 2.33, CH2Cl2); 1 H NMR(300 MHz, CDCl3) δ 7.44~7.42(d, J = 8.5 Hz, 2H), 7.13~7.11(d, J = 8.2 Hz, 2H), 4.88~4.81(m, 2H), 4.22~4.16 (m, 3H), 4.04~3.97(q,J = 7.1,6.9 Hz, 2H), 3.78~3.75(d, J = 9.4 Hz, 1H), 1.26~1.21(t, J = 7.2,7.1 Hz, 3H), 1.08~1.03(t, J = 7.1,7.1 Hz, 3H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.42, 166.83, 135.52, 132.29, 130.00, 122.62, 77.55, 62.50, 62.26, 54.86, 42.60, 14.17, 13.99 ppm; IR(KBr) 2983, 2950, 1732, 1556, 1490, 1445 cm -1 HRMS(ESI) for C 15 H 19 N1O6Br[M+H] + Calcd: 388.03903 Found: 388.04495; HPLC [Chiralcel AD-H, hexane / ethanol = 95 / 5, 1.0 mL / min, λ= 254 nm, retention times:(major) 35.9 min,(minor) 44.4 min].
[0234] (8) (R)-diethyl 2-(1-(4-chlorophenyl)-2-nitroethyl)malonate( 2h , 화학식 5b-8)
[0235]
[0236] [α] D 20 = -0.24( c 0.43, CH2Cl2); 1 H NMR(300 MHz, CDCl3) δ 7.29~7.17(dd, J = 20.6,8.2 Hz, 4H), 4.88~4.81(m, 2H), 4.23~4.16(m, 3H), 4.04~3.97(q, J = 7.1,7.1 Hz, 2H), 3.78~3.75(d, J= 9.3 Hz, 1H), 1.26~1.21(t, J = 7.1,7.2 Hz, 3H), 1.08~1.03(t, J = 7.2,6.8 Hz, 3H) ppm; 13 C NMR(100 MHz, CDCl3) δ167.44, 166.83, 134.98, 134.46, 129.69, 129.32, 77.63, 62.49, 62.23, 54.92, 42.55, 14.15, 13.97 ppm; IR(KBr) 2984, 1733, 1557, 1478, 1445, 1371 cm -1 HRMS(ESI) for C 15 H 19 N1O6Cl[M+H] + Calcd: 344.08954 Found: 344.09119; HPLC [Chiralcel AD-H, hexane / ethanol = 90 / 10, 1.0 mL / min, λ= 254 nm, retention times:(major) 17.9 min,(minor) 24.1 min].
[0238] Example 3.2. ( R )-4-Phenylpyrrolidin-2-one(4d, chemical formula 6b)
[0239] [α] D 20 -32.1( c 1.0, MeOH);
[0240] 1 H NMR(500 MHz, CDCl3) δ7.37~7.33(m, 2H), 7.29~7.27(m, 2H), 7.26~7.25(m, 1H), 5.92(br s, 1H), 3.81~3.77(m, 1H), 3.71(q, J = 8.0 Hz, 1H), 3.45~3.41(dd, J = 9.4, 2.0 Hz, 1H), 2.77~2.72(dd, J = 16.8, 8.7 Hz, 1H), 2.54~2.49(dd, J= 17.0, 8.5 Hz, 1H) ppm; 13 C NMR (125 MHz, CDCl3) δ 177.93, 142.14, 128.88, 127.13, 126.79, 49.60, 40.31, 38.02 ppm; LRMS (ESI + ) for C 10 H 11 NO[M+H] + Calcd: 162.1, Found: 162.2; HPLC [Chiralcel AD-H, hexane / 2-propanol = 90 / 10, flow rate =1.0 mL / min, λ=254 nm, retention times:(minor) 15.2 min,(major) 19.4 min]; R f ( SiO2, EtOAc) = 0.30
[0242] Example 3.3. (R)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide hydrochloride (5b, chemical formula 1b)
[0243] [α] D 20 = +7.4(c = 1.0, MeOH);
[0244] N-carbamoyl methyl-4-phenyl-2-pyrrolidinone chloride (85%) was obtained by synthesizing in the same manner as in Example 2.4.
[0245] 1 H NMR spectrum (DMSO- d 6), δ, ppm: 2.41 dd(1H, 3-H), 2.72 dd(1H, 3-H), 3.42 m(1H, 5-H), 3.59 m(1H, 4-H), 3.79 m(1H, 5-H), 4.00 dd(2H, NCHCO); 7.24-7.36 m(5H, Ph). 13 C NMR spectrum (DMSO- d 6), δC, ppm: 37.01, 38.48, 44.04, 54.55, 127.16, 127.35, 129.08, 143.35, 170.64, 173.84 pp; LRMS (ESI+ ) for C 10 H 14 ClNO2[M] + Calcd: 254, Found: 254;
[0247] Example 4. Preparation of (R)-Phenylpiracetam Hydrazide Hydrochloride (Chemical Formula 1d)
[0248]
[0249] The method for preparing (R)-phenylpyracetam hydrazide hydrochloride (Chemical Formula 1d), which is a pharmaceutically acceptable salt of a (R)-type chiral gamma lactam derivative according to one embodiment of the present invention, is the same as Reaction Scheme 3 above, and (R)-4-Phenylpyrrolidin-2-one (4d, Chemical Formula 6b) was obtained in the same way as in Example 3.
[0250] Subsequently, a solution of 4-phenyl-2-pyrrolidinone (1.0 equivalent) in 1,4-dioxane (30 ml) was added to a suspension of sodium hydride (1.1 equivalent) in 1,4-dioxane (30 ml). The mixture was heated at 90 °C for 30 minutes and then cooled to room temperature. Ethyl bromoacetate (1.1 eq.) was added, and the reaction mixture was refluxed at 120 °C for 6 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using an ethyl acetate-hexane mixture in a 1:1 ratio to obtain N-ethoxycarbonylmethyl-4-phenyl-2-pyrrolidinone. A solution of N-ethoxycarbonylmethyl-4-phenyl-2-pyrrolidinone (250 mg, 1.01 mM) in methanol (30 ml) was saturated with a gaseous ammonia stream for 5 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography with an ethyl acetate-hexane mixture 1:1 silica gel and concentrated under reduced pressure. The concentrate was dissolved in ethanol (30 ml) with hydrazine hydrate (1.1 equivalents), stirred at room temperature for 1 hour, and then concentrated. The concentrate was added to 6 N HCl and dissolved by stirring, then concentrated again under reduced pressure to obtain N-carbamoylmethyl-4-phenyl-2-pyrrolidinone hydrazine chloride (87%).
[0251] 1 H NMR spectrum (DMSO- d 6), δppm: 2.51 dd(1H, 3-H), 2.70 dd(1H, 3-H), 3.43 m(1H, 5-H), 3.62 m(1H, 4-H), 3.77 m(1H, 5-H), 3.87 dd(2H, NCHCO), 4.26 br.s(2H, NH-NH2), 7.24-7.34 m(5H, Ph), 9.19 br.s(1H, CONH). 13 C NMR spectrum (DMSO- d6), δppm: 36.47, 37.99, 43.54, 54.07, 126.68, 126.90, 128.61, 142.88, 170.20, 173.30 pp; LRMS (ESI + ) for C 12 H 16 ClNO2[M+H] + Calcd: 270, Found: 270;
[0253] Experimental Example 1. In vitro efficacy analysis of the chiral gamma lactam derivative of the present invention or a pharmaceutically acceptable salt thereof
[0254] The efficacy of the chiral gamma lactam derivatives of the present invention or their pharmaceutically acceptable salts in controlling symptoms of myopathic, psychiatric, and neurodegenerative diseases was analyzed using human kidney, skeletal muscle, and nerve cell lines. It was confirmed that the effect of the calcium excretion control mechanism is excellent through chiral modulation and derivatization, and cytotoxicity analysis confirmed that there are no ties with natural amino acids. As a result of confirming the intracellular mode of action, it was confirmed that the derivatives of the present invention or their pharmaceutically acceptable salts inhibit MAO-B as D1-mGlu5 targets and regulate calcium channels. In addition, the control of the myostatin regulator (TNF-beta), a sarcopenia marker, and the inhibition of protein expression were confirmed.
[0256] Experimental Example 1.1. Intracellular Ca using Confocal Laser Scanning Microscope (CLSM) 2+ Concentration measurement
[0257] Intracellular Ca 2+ To detect levels, the human renal epithelial cell line HEK293T was seeded in 35 mm diameter confocal dishes 24 hours prior to the experiment and cultured to 40–60%. Cells were loaded with 5 mM fluorescent radioactive calcium indicator Fluo-3-acetoxymethyl (Fluo-3-AM; Invitrogen) for 30 minutes at 37 °C. Ca 2+Concentrations were determined using CLSM (Zeiss LSM 700 Meta; Zeiss, Oberkochen, Germany). After washing with medium, culture plates were placed on a temperature-controlled microscope stage and observed at 200X magnification. The excitation and emission wavelengths for signal detection were 488 and 515 nm, respectively. Analysis of intracellular calcium intensity was performed using Zen software (Carl Zeiss).
[0258] As a result, the intracellular calcium intensity was highest at 18 seconds and then gradually decreased as calcium was released (Fig. 1). Compared to the control, rasagiline, and the comparative example, (R)-phenylpiracetam, the Ca2+ release performance of the pharmaceutically acceptable salts of the chiral gamma lactam derivative according to one embodiment of the present invention, namely Ph-10 (Formula 1d), Ph-20 (Formula 1a), and Ph-30 (Formula 1b), was significantly superior (Figs. 2 and 3). In particular, the (R) type Ph-30 showed a performance difference of more than 2 times compared to the (S) type Ph-20, and it was confirmed that when the hydrochloride was substituted, there was a difference in calcium release performance of more than 1.5 to 3 times. This is expected to be a result of the effect of promoting non-binding interactions in drug-receptor complexes, as the molecular polarity characteristics are enhanced as the polarity and dipole moment increase compared to phenylpiracetam in the case of pH-10, 20, and 30 compounds.
[0261] Experimental Example 1.2. Human Skeletal Myoblast (HSkM) Differentiation Induction Test
[0262] Human skeletal myoblasts (HSkM) prepared in a 24-well plate for the human skeletal myoblast differentiation induction test (3 x 10 5The test substance was added to cells / wells and cultured in a 37°C CO2 incubator for 48 hours. After 24 and 48 hours of culture, the cell culture supernatant was collected in E-tubes and stored in a deep freezer; for ELISA analysis, the supernatant was thawed to perform the test. The ELISA analysis was conducted based on the test method specified in the ELISA kit.
[0263] As a result, the pH-30 compound reduced the GDF-8 / Myostatin level the most, and compared to the IGF-1 treatment group and the (R)-phenylpiracetam (Ph-pira) treatment group, the pH-10 and pH-20 compounds showed equivalent or superior performance (Fig. 4). In addition, it was confirmed that the pH-30 compound lowered the SMAD2 and SMAD3 levels the most, and compared to the (R)-phenylpiracetam treatment group, the pH-10 and pH-20 compounds also showed effective performance (Fig. 5).
[0265] Experimental Example 1.3. Confirmation of changes in mRNA expression related to neuroinflammation and apoptosis
[0266] After inducing an inflammatory response in human neuroblastoma SH-SY5Y cell lines by treating them with 2.5 mM MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), mRNA expression of SYP (synaptophysin), GAP-43 (Growth-associated protein-43), MAO-B (Monoamine oxidase-B), and iNOS (inducible nitric oxide synthase) was confirmed by real-time PCR.
[0267] As a result of confirming SYP mRNA expression, mRNA expression was significantly increased when treated with the chiral gamma lactam derivatives of the present invention or their pharmaceutically acceptable salts (Ph-10, 20, 30) compared to the group treated with MPTP alone. As a result of confirming GAP-43 mRNA expression, mRNA expression was significantly increased in the group treated with the Ph-10 compound compared to the group treated with MPTP alone. In the case of iNOS and MAO-B, mRNA expression was significantly decreased in the groups treated with the Ph-10 and 30 compounds compared to the group treated with MPTP alone (Fig. 6a). In particular, in the case of the Ph-30 compound, the increased Ca after MPTP treatment 2+ It was confirmed through fluorescence microscopy that it significantly reduced superoxide anions (Fig. 6b).
[0269] Experimental Example 2. In vivo efficacy analysis of the chiral gamma lactam derivative of the present invention or a pharmaceutically acceptable salt thereof
[0270] Six-month-old normal mice were acclimatized for one week and trained for behavioral tests, after which they were randomly divided into groups. To construct a Parkinson's disease mouse MPTP model, mice were treated with the chiral gamma-lactam derivative of the present invention or its pharmaceutically acceptable salt (dissolved in 0.9% saline, intraperitoneal injection (ip)) for three days, followed by MPTP (dissolved in 0.9% saline, ip) for five consecutive days. Upon MPTP treatment, cerebellar damage occurs, resulting in hypotonia and impaired motor control. For the control group, the same volume of physiological saline (ip) was provided. Two days after the last injection, efficacy was confirmed through the open field test (OFT), forced swim test (FST), rotarod test, and pilocarpine-induced seizure evaluation.
[0271] Furthermore, blood analysis confirmed a decrease in blood myostatin levels, a marker related to sarcopenia, and verified that there was no toxicity to liver, kidney, or myocardial function. The mechanism of action was confirmed through skeletal muscle tissue analysis, calcium levels, motility, and blood tests.
[0273] Experimental Example 2.1. Open Field Inspection (OFT)
[0274] To measure general exercise activity levels and behavioral anxiety, an open field test was performed. (1) First, 30 minutes before performing the open field test, a chiral gamma lactam derivative of the present invention or a pharmaceutically acceptable salt thereof and Bechcle (saline, test drug) were injected intraperitoneally and video recorded for 10 minutes. (2) Video analysis was performed to check for sedation and the distance traveled was measured.
[0275] As a result of treating with the pH-30 compound at concentrations of 5, 10, and 15 mg / kg, the distance traveled increased compared to the control group at all concentrations. Although there were differences in the total distance traveled depending on the concentration, 10 mg / kg was used in subsequent experiments because there was a possibility that there would be no effect at very low concentrations (Fig. 7a).
[0276] MPTP alone was used as the negative control, and selegiline was used as the positive control. Compared to the MPTP alone and Selegiline groups, as well as the (R)-phenylpiracetam (Ph-pira) group, the total distance traveled increased when treated with the chiral gamma lactam derivative of the present invention or its pharmaceutically acceptable salt (Ph-10, 20, 30). In particular, the pH-30 group showed a value approximately three times higher than that of the MPTP alone group (Fig. 7b). This suggests that the derivative of the present invention or its pharmaceutically acceptable salt increases motility and has an anti-anxiety effect.
[0278] Experimental Example 2.2. Forced Swim Test (FST)
[0279] A forced swimming test (FST) was performed to induce depressive behavior in mice. (1) First, a 2L beaker was filled with water (25±1 ℃) to a depth of about 10 cm, and mice were allowed to swim, then returned to their rearing cages after 6 minutes. (2) The group under restraint stress was confined in a restraint tube for 90 minutes up to 60 minutes before the forced swimming test, and then allowed to swim as in (1), and returned to their rearing cages. (3) At this time, the chiral gamma lactam derivative of the present invention or a pharmaceutically acceptable salt thereof was injected into the abdominal cavity 30 minutes before the forced swimming test (saline, test drug). The immobility time of 4 minutes out of 6 minutes was measured and compared between the groups.
[0280] As a result, the group treated with MPTP alone exhibited an average immobility time approximately twice as long as the control group (saline) that received no treatment. In the case of the phenylpiracetam-treated group, the immobility time decreased compared to the group treated with MPTP alone; however, when treated with the chiral gamma lactam derivative of the present invention or its pharmaceutically acceptable salt (Ph-10, 20, 30), a lower immobility time was observed. This is a statistically significant difference, indicating that the chiral gamma lactam derivative of the present invention or its pharmaceutically acceptable salt has an antidepressant effect. In particular, the pH-30 compound tended to exhibit a lower immobility time than the control group that received no treatment, suggesting that it has a particularly excellent antidepressant effect (Fig. 8).
[0282] Experimental Example 2.3. Rotarod Inspection
[0283] To evaluate the gait and motor abilities of the lower extremities, a rotarod test was performed for 5 weeks. Motor coordination and balance were assessed by measuring the latency to fall when a mouse was placed on a rotating rod. MPTP was injected intraperitoneally into mice at a concentration of 30 mg / kg for 5 consecutive days. One week after MPTP injection, the drug (15 mg / kg) was administered intraperitoneally twice a week. The mice were placed on a rotarod consisting of a rotarod 60 cm high, with a diameter of 7 cm and six partitions spaced 15 cm apart, and the time taken to fall was measured while the rod rotated at a speed of 5 rpm to 50 rpm (maximum speed) for 180 seconds. During this time, the mice were sufficiently trained to adapt to the test during the experimental period.
[0284] As a result, compared to the control group and the group treated with MPTP alone, motility increased in all cases treated with the chiral gamma lactam derivative of the present invention or its pharmaceutically acceptable salts (Ph-10, 20, 30) (Fig. 9a). In addition, after 5 weeks, the muscle weight of both the tibialis anterior (TA) and the extensor digitorum longus (EDL) increased at a statistically significant level (Figs. 9b and 9c). In particular, the Ph-30 compound showed approximately twice the efficacy compared to the Ph-20 compound, which is attributed to the difference in chirality.
[0286] Experimental Example 2.4. Evaluation of pilocarpine-induced seizures
[0287] A pilocarpine-induced seizure mouse model was constructed to study changes in brain activity. Pilocarpine is an agonist that increases cell activity by binding to muscarinic cholinergic receptors in neurons and is used to construct a model of mesial temporal lobe epilepsy.
[0288] Experiments were conducted on surgically operated male mice C57BL / 6J under a constant environment (24–25°C, 50–60% humidity, 12-hour light / dark cycle). As a pretreatment to suppress the side effects of pilocarpine, methylscopolamine-bromide (1 mg / kg) was injected intraperitoneally 30 minutes prior to the pilocarpine injection, and the chiral gamma lactam derivative of the present invention or its pharmaceutically acceptable salt (15 mg) was injected intraperitoneally 25 minutes prior to the pilocarpine injection. Pilocarpine (Sigma, Deisenhofen, Germany) was injected intraperitoneally at a single dose of 330 mg / kg, and behavioral and electrophysiological seizure patterns were observed for 24 hours. Status epilepticus (SE) began after several seizures.
[0289] Seizure patterns were classified into the following five categories, and cases (4) and (5) were defined as convulsive seizures, and the frequency and duration were analyzed. (0) cases without convulsive behavior; (1) facial clonus; (2) head nodding; (3) forelimb clonus; (4) reing; (5) reing and falling back.
[0290] As a result, as shown in Figure 10, the total number of convulsive seizures was significantly lower for the pH-30 compound compared to the control group, and the pH-10 compound also showed similar efficacy. In the case of the pH-20 compound, the number was higher, but it was confirmed that the number was effectively reduced compared to the control group or the (R)-phenylpiracetam treatment group.
[0292] Experimental Example 2.5. Confirmation of changes in expression of sarcopenia-related markers
[0293] MPTP was injected into the peritoneal cavity of mice at a concentration of 30 mg / kg for 5 consecutive days. One week after the MPTP injection, mice were administered intraperitoneally at a concentration of 15 mg / kg twice a week for 5 weeks with the chiral gamma lactam derivative of the present invention or its pharmaceutically acceptable salt (Ph-10, 20, 30), and changes in the expression levels of GDF-8 / Myostatine, a sarcopenia-related marker, in mouse serum were checked.
[0294] The expression levels of GDF-8 / Myostatin in mouse serum were observed to be relatively lower for all pH-10, 20, and 30 compounds compared to the IGF-1 treated group and the (R)-phenylpiracetam treated group at a statistically significant level. In mouse experiments, as in cell experiments (Experimental Example 1.3), differences based on chirality were confirmed, and it was confirmed that the expression level of the pH-30 compound was the lowest (Fig. 11). This suggests that the chiral gamma lactam derivatives of the present invention or their pharmaceutically acceptable salts can be utilized as therapeutic agents for muscle diseases such as sarcopenia.
[0296] Although the embodiments have been described above with reference to the limited drawings, those skilled in the art can apply various technical modifications and variations based on the above. For example, suitable results may be achieved even if the described techniques are performed in a different order than described, and / or if the components of the described system, structure, device, circuit, etc. are combined or assembled in a form different from described, or replaced or substituted by other components or equivalents.
[0297] Therefore, other implementations, other embodiments, and equivalents to the claims also fall within the scope of the claims set forth below.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of a muscle disease comprising, as an active ingredient, a chiral gamma lactam derivative represented by the following [Chemical Formula 1c] or a pharmaceutically acceptable salt thereof, wherein the muscle disease is one or more of sarcopenia, muscular atrophy, and muscular dystrophy: [Chemical Formula 1c] . Claim 2 A pharmaceutical composition according to claim 1, characterized in that the pharmaceutically acceptable salt of the chiral gamma lactam derivative represented by [Chemical Formula 1c] is a salt represented by the following [Chemical Formula 1d]. [Chemical Formula 1d] . Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 A method for preparing a chiral gamma lactam derivative represented by [Formula 1a] comprising the following steps: (1) preparing a compound represented by [Formula 4a] from a compound represented by [Formula 3a] using a catalyst compound represented by [Formula 2]; (2) preparing a compound represented by [Formula 5a] from a compound represented by [Formula 4a]; (3) preparing a compound represented by [Formula 6a] from a compound represented by [Formula 5a]; and (4) preparing a compound represented by [Formula 1a] by treating a compound represented by [Formula 6a] with sodium hydride (NaH), ethyl bromoacetate (BrCH2COOEt), and ammonia (NH3); [Formula 1a] ;[Chemical Formula 2] ;[Chemical Formula 3a] ;[Chemical Formula 4a] ;[Chemical Formula 5a] ;[Chemical Formula 6a] ; In the above formula 2, R1 and R2 are identical or different from each other and are each one or more selected from the group consisting of hydrogen, a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, a C3-C8 aryl group, and combinations thereof; R3 is a C3-C8 aryl group, and one or more hydrogens of the aryl group are unsubstituted or substituted with one or more selected from the group consisting of a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, and combinations thereof; and in the above formula 5a, R4 is hydrogen or a halogen group. Claim 7 A method of manufacturing according to claim 6, wherein the catalyst compound represented by [Chemical Formula 2] is one or more selected from the group consisting of catalyst compounds represented by [Chemical Formula 2-1] to [Chemical Formula 2-11] and combinations thereof. [Chemical Formula 2-1] ;[Chemical Formula 2-2] ;[Chemical Formula 2-3] ;[Chemical Formula 2-4] ;[Chemical Formula 2-5] ;[Chemical Formula 2-6] ;[Chemical Formula 2-7] ;[Chemical Formula 2-8] ;[Chemical Formula 2-9] ;[Chemical Formula 2-10] ;[Chemical Formula 2-11] . Claim 8 A method of preparation according to claim 6, wherein the compound represented by [Chemical Formula 5a] is one or more selected from the group consisting of compounds represented by [Chemical Formula 5a-1] and [Chemical Formula 5a-2] and combinations thereof. [Chemical Formula 5a-1] ;[Chemical Formula 5a-2] . Claim 9 A method for preparing a chiral gamma lactam derivative represented by [Formula 1b] comprising the following steps: (1) preparing a compound represented by [Formula 4b] from a compound represented by [Formula 3b] using a catalyst compound represented by [Formula 2]; (2) preparing a compound represented by [Formula 5b] from a compound represented by [Formula 4b]; (3) preparing a compound represented by [Formula 6b] from a compound represented by [Formula 5b]; and (4) preparing a compound represented by [Formula 1b] by treating a compound represented by [Formula 6b] with sodium hydride (NaH), ethyl bromoacetate (BrCH2COOEt), and ammonia (NH3); [Formula 1b] ;[Chemical Formula 2] ;[Chemical Formula 3b] ;[Chemical Formula 4b] ;[Chemical Formula 5b] ;[Chemical Formula 6b] ; In the above formula 2, R1 and R2 are identical or different from each other and are each one or more selected from the group consisting of hydrogen, a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, a C3-C8 aryl group, and combinations thereof; R3 is a C3-C8 aryl group, and one or more hydrogens of the aryl group are unsubstituted or substituted with one or more selected from the group consisting of a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, and combinations thereof; and in the above formula 5b, R4 is hydrogen or a halogen group, and R5 is a C1-C6 alkyl group or a benzyl group. Claim 10 A method of preparation according to claim 9, wherein the compound represented by [Chemical Formula 5b] is one or more selected from the group consisting of compounds represented by [Chemical Formula 5b-1] to [Chemical Formula 5b-8] and combinations thereof. [Chemical Formula 5b-1] ;[Chemical Formula 5b-2] ;[Chemical Formula 5b-3] ;[Chemical Formula 5b-4] ;[Chemical Formula 5b-5] ;[Chemical Formula 5b-6] ;[Chemical Formula 5b-7] ; and [Chemical Formula 5b-8] . Claim 11 A method for preparing a pharmaceutically acceptable salt of a chiral gamma lactam derivative represented by [Formula 1d] comprising the following steps: (1) preparing a compound represented by [Formula 4b] from a compound represented by [Formula 3b] using a catalytic compound represented by [Formula 2]; (2) preparing a compound represented by [Formula 5b] from a compound represented by [Formula 4b]; (3) preparing a compound represented by [Formula 6b] from a compound represented by [Formula 5b]; and (4) preparing a compound represented by [Formula 1d] by treating a compound represented by [Formula 6b] with sodium hydride (NaH), ethyl bromoacetate (BrCH2COOEt), and hydrazine hydrate; [Formula 1d] ;[Chemical Formula 2] ;[Chemical Formula 3b] ;[Chemical Formula 4b] ;[Chemical Formula 5b] ;[Chemical Formula 6b] ; In the above formula 2, R1 and R2 are identical or different from each other and are each one or more selected from the group consisting of hydrogen, a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, a C3-C8 aryl group, and combinations thereof; R3 is a C3-C8 aryl group, and one or more hydrogens of the aryl group are unsubstituted or substituted with one or more selected from the group consisting of a C1-C6 alkyl group, a halogen group, a cyano group, a nitro group, a trifluoromethyl group, an alkoxy group, and combinations thereof; and in the above formula 5b, R4 is hydrogen or a halogen group, and R5 is a C1-C6 alkyl group or a benzyl group.
Citation Information
Patent Citations
2-oxo-1-pyrrolidine derivatives, processes forpreparing them and their uses
KR1020020075926A
